Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | PAK3 | O75914 | 1/20 | 0.34 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22535446 | 0.88 | NTRK1 (0.40) | NTRK1JAK2JAK3ALKPAK1 | |
| SCHEMBL22535381 | 0.88 | NTRK1 (0.46) | NTRK1JAK2JAK3P2RX3PAK1 | |
| SCHEMBL22535759 | 0.88 | NTRK1 (0.40) | NTRK1JAK2JAK3ALKPAK1 | |
| SCHEMBL22535438 | 0.87 | NTRK1 (0.49) | NTRK1JAK2JAK3ALKPAK1 | |
| SCHEMBL22535433 | 0.87 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535423 | 0.87 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL20575168 | 0.87 | NTRK1 (0.53) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535336 | 0.86 | NTRK1 (0.47) | NTRK1JAK2JAK3PAK1PAK3 | |
| SCHEMBL22535671 | 0.83 | NTRK1 (0.49) | NTRK1JAK2JAK3PAK1PAK4 | |
| SCHEMBL22535556 | 0.82 | NTRK1 (0.43) | NTRK1JAK2JAK3ALKPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885JAK2 833/4885JAK3 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.